Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Kallikrein 15 Antibodies:
anti-Human Kallikrein 15 Antibodies:
anti-Rat (Rattus) Kallikrein 15 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Kallikrein 15 Primary Antibody for EIA, IHC (p) - ABIN953102
Rabien, Fritzsche, Jung, Tölle, Diamandis, Miller, Jung, Kristiansen, Stephan: KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. in International journal of cancer. Journal international du cancer 2010
Show all 3 references for ABIN953102
Human Polyclonal Kallikrein 15 Primary Antibody for IHC (p), WB - ABIN658745
Gallagher, Vijai, Cronin, Bhatia, Vickers, Gaudet, Fine, Reuter, Scher, Halldén, Dutra-Clarke, Klein, Scardino, Eastham, Lilja, Kirchhoff, Offit: Susceptibility loci associated with prostate cancer progression and mortality. in Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Show all 2 references for ABIN658745
Variations in KLK15, but not KLK11 (show KLK11 Antibodies) expression were significantly associated with prognosis in gastric cancer
Advanced pathologic stage was associated with significantly higher expression of KLK15 and PCA3 mRNAs.
KLK15 mRNA expression levels are a novel marker for the differential diagnosis of prostate cancer.
These findings suggest a role for KLK15 genetic variation in the etiology of prostate cancer among men of European ancestry.
Multivariate analysis identified dichotomised KLK15 expression, corrected for patient parameters age, preoperative prostate-specific antigen (show KLK3 Antibodies) level, pathological tumour stage, Gleason score and surgical margins, as an prognostic factor for poor outcome.
KLK15 expression analysis could be employed as a valuable tool for the discrimination between benign prostatic hyperplasia and prostate cancer tissue specimens and as an unfavorable prognostic marker for prostate cancer.
Data show six non-synonymous amino acid or frame shift changes in the KLK3 (show KLKB1 Antibodies) gene and three changes in each of the neighboring genes, KLK15 and KLK2 (show KLK2 Antibodies).
Kallikrein 15 expression is an independent prognostic factors of progression-free and overall survival in breast cancer patients
KLK15 expression, as assessed by quantitative RT-PCR, is an independent marker of unfavorable prognosis for ovarian cancer.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In prostate cancer, this gene has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer. The gene contains multiple polyadenylation sites and alternative splicing results in multiple transcript variants encoding distinct isoforms.
, ACO protease
, kallikrein-like serine protease